Bristol Myers Squibb (CELG-RI) Invested Capital (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Invested Capital for 18 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Invested Capital fell 78.22% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $10.1 billion (down 11.31% YoY), while the FY2025 annual figure was $2.3 billion, up 10.51% from the prior year.
• Invested Capital retreated to $1.0 billion in Q2 2026 per CELG-RI's latest filing, from $2.3 billion in the prior quarter.
• Across five years, Invested Capital topped out at $7.5 billion in Q1 2022 and bottomed at $1.0 billion in Q2 2026.
• Historically, Invested Capital has averaged $3.6 billion across 5 years, with a median of $3.3 billion in 2023.
• Annual changes were most pronounced in 2022 — Invested Capital surged 323.3% — and 2024, when it sank 80.28%.
• Bristol Myers Squibb's Invested Capital stood at $4.3 billion in 2022, then fell by 26.85% to $3.1 billion in 2023, then slumped by 34.4% to $2.0 billion in 2024, then advanced by 10.51% to $2.3 billion in 2025, then plunged by 54.58% to $1.0 billion in 2026.
• Business Quant data shows CELG-RI's Invested Capital at $1.0 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.3 billion in Q4 2025.